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Ewing sarcoma is the second most common pediatric bone tumor, with three cases per 
million worldwide. In clinical terms, Ewing sarcoma is an aggressive, rapidly fatal malig-
nancy that mainly develops not only in osseous sites (85%) but also in extra-skeletal soft 
tissue. It spreads naturally to the lungs, bones, and bone marrow with poor prognosis in 
the two latter cases. Bone lesions from primary or secondary (metastases) tumors are 
characterized by extensive bone remodeling, more often due to osteolysis. Osteoclast 
activation and subsequent bone resorption are responsible for the clinical features of 
bone tumors, including pain, vertebral collapse, and spinal cord compression. Based on 
the “vicious cycle” concept of tumor cells and bone resorbing cells, drugs, which target 
osteoclasts, may be promising agents as adjuvant setting for treating bone tumors, 
including Ewing sarcoma. There is also increasing evidence that cellular and molecular 
protagonists present in the bone microenvironment play a part in establishing a favorable 
“niche” for tumor initiation and progression. The purpose of this review is to discuss the 
potential therapeutic value of drugs targeting the bone tumor microenvironment in Ewing 
sarcoma. The first part of the review will focus on targeting the bone resorbing function of 
osteoclasts by means of bisphosphonates or drugs blocking the pro-resorbing cytokine 
receptor activator of NF-kappa B ligand. Second, the role of this peculiar hypoxic micro-
environment will be discussed in the context of resistance to chemotherapy, escape 
from the immune system, or neo-angiogenesis. Therapeutic interventions based on 
these specificities could be then proposed in the context of Ewing sarcoma.
Keywords: ewing sarcoma, bone remodeling, bisphosphonate, RANKL, microenvironment, tumor bone niche, 3D 
models
iNTRODUCTiON
ewing Sarcoma: A Clinical Presentation
Ewing sarcoma was first described by James Ewing in 1921. It is a high-grade neoplasm, and it is the 
second most common primary bone malignancy in both children and adolescents (1). With peak 
incidence at 15 years, this disease accounts for 2% of childhood cancers (2). Ewing sarcoma is defined 
as a bone tumor, which may occur at any site within the skeleton but preferentially affects the trunk 
and the diaphysis of long bones (2). However, it may occur in extra-skeletal soft tissue in 15% of 
cases. It is characterized by rapid tumor growth and extensive bone destruction (Figure 1) that can 
FiGURe 1 | X-ray of typical severe osteolytic lesions in a ewing 
sarcoma patient (arrows: severe osteolytic lesions).
December 2015 | Volume 5 | Article 2792
Redini and Heymann Bone Microenvironment in Ewing Sarcoma
Frontiers in Oncology | www.frontiersin.org
result in bone pain and pathological fracture (3). At the histologi-
cal level, Ewing sarcoma appears as small, poorly differentiated, 
round tumor cells positive for the transmembrane glycoprotein 
CD99 staining (4).
The molecular event that initiates the Ewing’s family of tumors 
is a typical chromosomal translocation that occurs in cells of mes-
enchymal origin and that fuses the EWS gene on chromosome 
22q12 to a member of the erythroblast transformation sequence 
(ETS) transcription gene family, most commonly FLI-1, on 11q24 
in 85% of cases (5–7). This translocation leads to the production 
of the oncogenic fusion gene EWS-FLI1, an aberrant transcrip-
tion factor that promotes tumorigenicity (8, 9). The presence of 
this fusion gene, which represents the Ewing sarcoma signature, 
is used as a specific diagnostic marker of the Ewing’s family of 
tumors thanks to fluorescence in situ hybridization and RT-qPCR 
(10). Numerous biological pathways, such as those involving 
insulin-like growth factor receptor (IGFR), platelet-derived 
growth factor receptor (PDGFR), vascular endothelial growth 
factor receptor (VEGFR), Sonic HedgeHog (SHH) pathway acti-
vation, Wnt, and transforming growth factor (TGF)-β receptor II 
pathway inhibition, are modulated by EWS-FLI1 activity, leading 
to proliferation, angiogenesis, immune system escape, metastatic 
potential, and treatment resistance that contribute to the Ewing 
sarcoma malignant phenotype (11).
Therapeutic Limits
The on-going treatments for Ewing sarcoma patients are effective 
in more than 70% of patients with localized disease. They elicit 
clinical responses in patients with metastatic disease but are not 
curative due to acquired resistance. Before the 1970s, amputation 
was the main therapeutic option, with 5-year survival of <20%. 
The introduction of first radiation and then chemotherapy 
in the 70s has modified the prognostic significantly, with the 
5-year event-free survival rate for localized tumors at around 
65%, and the overall survival rate close to 75%. However, the 
survival rates decrease to 15–25% when metastases are detected 
at diagnosis, or in patients presenting resistance to treatment or 
with relapsed disease. In the past three decades, conventional 
therapies seem to have attained a survival plateau for these 
metastatic patients (12).
Improved poly-chemotherapy has made it possible to limit 
surgery and salvage limb, but in about 20% of cases, bone sarcomas 
have already disseminated at the time of diagnosis. In most cases, 
the distant metastases are located in the lungs, followed by the skel-
eton. Although Ewing sarcoma patients with lung metastases have 
overall survival of 45% at 5 years, those with bone or bone marrow 
metastases have very poor prognosis, with <25% overall survival 
at 5 years. In the past, when therapy was limited to local control 
(surgery), nearly all patients who initially appeared to have a local-
ized tumor developed distant metastases (13). Ewing sarcoma thus 
needs to be considered as a systemic disease, requiring systemic 
treatment, i.e., combination chemotherapy, as a rule. However, 
systemic therapy can never replace definitive local control with 
surgery and/or radiotherapy. The therapy used for Ewing sarcoma 
therefore requires a combination of surgery or radiotherapy for 
localized control and high-intensity chemotherapy for localized 
and disseminated disease. The most recent protocol for Ewing 
tumors was the European Ewing tumor Working Initiative of 
National Groups 99 protocol (EuroEWING99, clinicaltrials.
gov no. NCT00020566), which tested the benefits of a different 
chemotherapy combination involving vincristine, ifosfamide, 
doxorubicin, and etoposide (VIDE). The protocol was composed 
of six sequences of VIDE treatment followed by surgery when 
possible. The histological response to chemotherapy was then 
evaluated and patients were divided into three arms depending 
on the localization of the tumor at diagnosis, the volume for 
unresected tumors, and the percentage of residual cells after treat-
ment. The R1 arm included patients with localized disease and a 
good response to chemotherapy (<10% of residual cells) or with 
a volume of <200  ml. The R2 arm included patients with lung 
metastases and patients with localized tumors and a poor response 
to chemotherapy, or with a volume of more than 200 ml. Finally, 
the R3 arm included patients with bone, bone marrow, or multifo-
cal metastases. The current survival rate for EuroEWING patients 
has attained 80% for localized disease of small volume (R1). 
Unfortunately, the 5-year survival rate for patients with metastases 
detected at diagnosis remains around 25% and even around 10% 
when relapse occurs within the first 2 years following treatment.
The current protocol for Ewing sarcoma patients is the 
EuroEWING2012 (clinicaltrials.gov no. NCT00987636), which 
started in December 2014 in Great Britain, with two randomiza-
tions: the first compares two chemotherapy protocols (with sur-
gery and/or radiotherapy) and the second randomizes patients 
with or without bisphosphonate zoledronate (zometa®).
Given that survival rates had not evolved in more than three 
decades, especially for metastatic patients with a very poor initial 
prognosis, there was an urgent need to define new therapeutic 
targets for Ewing sarcoma patients. In addition to the tumor cells 
themselves, targeting the bone tumor microenvironment appears 
to be promising.
The Bone Microenvironment is a 
Favorable “Niche” for Tumor Progression 
in Bone
Recently, there has been a dramatic increase in the importance 
given to the theory that the bone microenvironment participates 
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in determining the “bone niche” in the progression of bone 
tumors, and in establishing resistance processes to conventional 
therapies. The concept of “bone niche” is well-recognized in the 
context of hematological malignancies, such as leukemia (14) or 
multiple myeloma (15). The “niche” is a functional microenviron-
ment able to both promote the emergence of cancer stem cells and 
provide all factors required for their development. However, the 
bone niche is composed of numerous cell types (pre-osteoclasts, 
pre-osteoblasts, endothelial cells, macrophages, etc.) that are 
located in the bone matrix, and their functional coordination 
is a pre-requisite for maintaining the bone and bone niche 
microarchitecture.
Much research has been published on the role played by the 
bone microenvironment in establishing metastases in these 
organs, especially from breast or prostate carcinomas. The con-
cept of bone niche is also currently under discussion in the case of 
solid tumors, and strengthens the “seed and soil” theory proposed 
by Paget in 1887, in which tumor cells (“seeds”) colonize recep-
tive foci (“soil”) (16). These data are supported by the fact that 
specific molecules (such as cadherin and osteopontin) play a 
part in stabilizing cancer cells in bone niches, mimicking the cell 
interactions that take place during hemopoiesis, as identified in 
the pre-metastatic niche in breast carcinoma (17, 18). In addi-
tion, carcinoma cells grow well in bone, which stores a variety 
of cytokines and growth factors, and thus provides an extremely 
fertile environment for growing tumor cells (19, 20).
The “seed and soil” theory can be also envisaged for primary 
bone tumors, as tumor growth and metastasis often require 
constant interactions between tumor cells and their surrounding 
microenvironment (21–25). This hypothesis has been largely 
documented in the case of osteosarcoma (26, 27) and chondro-
sarcoma (28), but very little information is currently available for 
Ewing sarcoma.
The Concept of the vicious Cycle 
in ewing Sarcoma
Ewing sarcoma is characterized by extensive bone destruction, 
mainly due to osteolysis (Figure 1). Because Ewing sarcoma cells 
cannot directly degrade bone, osteoclast activation and subse-
quent bone resorption may be responsible for the clinical features 
of bone destruction in this pathology (3). Bone degradation is 
controlled by osteoclasts, whose differentiation and activation 
are mainly mediated by receptor activator of NF-kappa B ligand 
(RANKL), a member of the tumor necrosis factor (TNF) super-
family (TNFSF11) after it binds to its receptor RANK expressed 
at the surface of mature osteoclasts and osteoclast precursors 
(29) (Figure 2). Osteoprotegerin (OPG) acts as a decoy recep-
tor inhibiting osteoclast formation, function, and survival by 
preventing the binding of RANKL to its receptor RANK (26).
Interaction between tumor cells, tumor-derived humoral 
factors, and the bone marrow in the bone niche has been shown 
to be essential for bone tumor initiation and promotion (30, 
31). Targeting the bone microenvironment, and particularly 
osteoclast activation, may therefore be a promising adjuvant 
strategy for treating bone tumors, including Ewing sarcoma. The 
vicious cycle between osteoclasts, bone stromal cells/osteoblasts, 
and cancer cells has been hypothesized during the progression 
of primary bone tumors (32) (Figure  2). Tumor cells produce 
osteoclast activating factors, such as interleukin (IL)-6, TNF-α, or 
ParaThyroid Hormone-related Peptide (PTH-rP), which induce 
osteoclast differentiation and activation. When osteoclasts resorb 
bone, they allow the release of growth factors stored in the bone 
matrix (TGF-β, IGF-1, PDGF, etc.), which in turn activate tumor 
cell proliferation (32). Accordingly, inhibiting osteoclast activity 
is a promising approach for breaking the vicious cycle, and thus 
indirectly limiting local cancer growth.
In addition, new therapeutic options targeting hypoxia, 
angiogenesis, bone cells, or mediators in the particular bone 
microenvironment have been studied extensively at the preclini-
cal level, with the more promising now being proposed in clinical 
trials. This review will describe the most recent developments in 
such therapeutic options for Ewing sarcoma patients.
TARGeTiNG BONe CeLLS iN ewiNG 
SARCOMA
Therapeutic agents that target the bone environment and modu-
late bone metabolism have been studied in preclinical models of 
primary bone sarcomas, demonstrating a certain degree of efficacy 
in both osteosarcoma and Ewing sarcoma. Two main strategies 
are currently being developed: (i) the first directly targets osteo-
clasts (differentiation, activation, and functions), mainly using 
bisphosphonates (BPs), and (ii) the second targets the cytokine 
RANKL, the pivotal cytokine for regulating osteoclast activation.
Bisphosphonates
Bisphosphonates are the synthetic analogs of endogenous 
pyrophosphate, with a high resistance to protease degrada-
tion, and the ability to strongly inhibit bone resorption (33). 
They are composed of two phosphonate groups. The central 
oxygen atom in pyrophosphate is replaced by a carbon atom, 
which allows the substitution of two side groups, one of 
which is often an hydroxyl group, and the other defines the 
BP generation (Figure  3). Two main families can therefore 
be distinguished: nitrogen- and non-nitrogen-containing 
BPs, which act on osteoclasts by means of different molecular 
mechanisms. In both cases, the final result  –  common to 
both – is the induction of osteoclast apoptosis. BPs act either 
by inhibiting the recruitment, proliferation, and differentia-
tion of pre-osteoclasts or by impeding the resorptive activity 
of mature osteoclasts (34–37). Zoledronic acid (ZOL) belongs 
to the third generation of BPs, which is the most efficient 
for preventing bone lesions (38–40). As for other nitrogen-
containing BPs, ZOL inhibits the farnesyl diphosphate and 
geranylgeranyl diphosphate synthases, two enzymes involved 
in the mevalonate pathway necessary for the prenylation of 
small intracellular GTPases, such as Ras, Rho, or Rac (41). 
As the prenylation of these GTPases is essential for osteoclast 
function, their inhibition leads to osteoclast apoptosis as a result 
of the loss of the survival signal (42–44). Moreover, BPs may also 
inhibit bone resorption by increasing the production of OPG by 
human osteoblasts (45). OPG is the decoy receptor of RANKL, 
FiGURe 3 | Schematic representation of the different bisphosphonate (BP) families: simple non-N-containing BPs (etidronate and clodronate) and 
N-containing BPs (pamidronate, alendronate, idandronate, risedronate, and zoledronate).
FiGURe 2 | vicious cycle between ewing sarcoma cell proliferation and osteoclast activation. Tumor cells produce osteoclast activating factors (IL-6, 
TNF-α, etc.) that will induce osteoclast differentiation and activation. When they resorb bone, osteoclasts allow the release of growth factors stored in the bone 
matrix, such as IGF-1, FGFs, and TGF-β, which in turn activate tumor cell proliferation. This is the theory of the so-called “vicious cycle.” The molecular OPG/
RANKL/RANK triad plays a pivotal role in the regulation of bone resorption. OPG and RANKL are produced by osteoblasts and/or stromal cells, whereas RANK is 
expressed at the surface of osteoclasts and their precursors. OPG, osteoprotegerin; IL-6, interleukin-6; TNF, tumor necrosis factor; RANK, receptor activator of 
NF-kB; RANKL, RANK-ligand; IGF1, insulin-like growth factor1; TGF-β, transforming growth factor-β; FGFs, fibroblast growth factors.
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which inhibits the RANK/RANKL interaction that is essential 
for osteoclast differentiation and activation. In addition to the 
antiresorptive effect of ZOL, it has been shown to induce the 
death of tumor cell lines, such as myeloma, and breast and 
prostate carcinoma cells in several preclinical studies (39). It 
also appears to exert an inhibitory effect on cancer cell invasion 
and angiogenesis (46).
Despite several side effects reported after long-term treatment 
with BPs, including osteonecrosis of the jaw, BPs are currently 
under investigation in postmenopausal bone loss and bone 
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lesions of tumoral origin, such as bone metastases from breast 
and prostate cancer with variable clinical benefits (47, 48). A 
significant decrease in bone resorption was observed in these 
studies but with no unequivocal effects on survival or the occur-
rence of metastases. The clinical effects of BPs on bone metastases 
from lung cancer are also discussed, as are their effects on visceral 
metastases (49–52). The encouraging results reported on bone 
remodeling, as well as the ability of BPs, and in particular ZOL, 
to induce tumor cell death in vitro, make them good candidates 
for a therapeutic strategy in primary bone tumors. ZOL may 
effectively inhibit both bone resorption and tumor proliferation 
in the vicious cycle, making it more efficient. With regard to 
primary bone tumors, several studies have already demonstrated 
the benefits of using ZOL in osteosarcoma (53–56), in particular, 
promising preclinical results have been reported on survival and 
tumor growth (56). In this context, ZOL has recently been com-
bined with conventional chemotherapy and surgery for adult and 
pediatric patients in the French OS2006 phase III randomized 
clinical trial for osteosarcoma treatment. Following these results, 
other preclinical and clinical studies demonstrated the beneficial 
effect of BP treatment in osteosarcoma (57–61).
In Ewing sarcoma, despite improvements to chemotherapy 
protocols, the survival rate for patients with bone metastases 
remains very low. In this context, combining ZOL with current 
conventional chemotherapy may be a promising therapeutic 
option for both limiting tumor-associated osteolysis and pre-
venting the development of bone metastases, which is currently 
the main factor for a bad prognosis for this pathology (62). Few 
fundamental and preclinical studies have demonstrated an anti-
tumoral effect for ZOL on Ewing sarcoma cell lines (63, 64). Of 
these studies, our team has recently shown that ZOL significantly 
inhibits tumor cell viability by blocking the cell cycle in S-G2M 
phase transition and by promoting caspase-3 activation (65). 
Using preclinical models of Ewing sarcoma induced in athymic 
mice by injecting human Ewing sarcoma cells either in bone 
site or in soft tissue, ZOL alone significantly inhibited tumor 
development in bone sites, decreasing osteolytic lesions and 
improving mouse survival (65). On the contrary, the same doses 
of ZOL had no effect on Ewing sarcoma progression in soft tissue. 
These results can be explained by the high tropism of BPs for the 
calcified bone matrix, leading to their elevated concentration in 
bone tissue and their rapid clearance from blood and soft tissue. 
These data correlate with other studies on soft tissue tumors or 
visceral metastases (39). On the other hand, we demonstrated 
the synergistic effect of a combination of ZOL and ifosfamide, a 
conventional drug used in Ewing sarcoma clinical protocols, on 
tumor progression in soft tissue (65). These results correlate with 
previous studies showing a synergistic effect between BPs and 
chemotherapeutical agents and demonstrate the great benefit of 
using ZOL in Ewing sarcoma treatments as a means of reducing 
the chemotherapy doses and as a consequence, their side effects 
(58, 66–68).
With regard to invasion and migration, we have already 
published that treatment with ZOL inhibits Ewing sarcoma 
cell migration in  vitro in Boyden chambers and diminishes 
MMP-2 activity as revealed by zymography (69). In addition, 
less pulmonary metastases were observed in mice treated with 
ZOL compared to untreated animals, in a model of spontaneous 
metastases disseminated from primary Ewing sarcoma induced 
in bone (69).
For the transfer to clinical practice, one phase II study 
evaluating the combination of chemotherapy and pamidronate 
in osteosarcoma patients has demonstrated little impact on 
patient survival, but has been shown to improve the durability of 
limb reconstruction (61). In a recently completed phase I study, 
ZOL combined with conventional multi-drug chemotherapy was 
safe, but failed to reveal any significant differences in event-free 
or overall survival in patients with newly diagnosed metastatic 
osteosarcoma (70). There are three phase II/III trials currently 
in progress, evaluating the efficacy of ZOL as a single agent or an 
adjuvant to chemotherapy in localized and metastatic osteosar-
coma (NCT00691236 and NCT00470223) and in Ewing sarcoma 
(NCT00987636).
However, long-term use of BPs may impact bone growth and 
tooth eruption in young patients. In our laboratory, we have 
carried out preclinical studies on newborn mice treated or not 
with ZOL, using a protocol that reproduces the frequency and 
doses administered in humans. ZOL induces a reversible arrest 
in bone growth that was also observed in young patients treated 
with zometa® (71). For tooth eruption, irreversible inhibition was 
observed (72).
As several side effects have been reported with the clinical use 
of BPs (49, 50), another approach to decrease bone resorption 
could therefore be to target RANKL, the main cytokine involved 
in osteoclast differentiation.
Anti-RANKL Strategies
Bone remodeling is strongly regulated thanks to the molecular 
triad OPG–RANKL–RANK (26). The binding of RANKL to its 
receptor RANK, expressed on the surface of osteoclast precur-
sors, induces osteoclast differentiation in  vitro in addition to 
macrophage-colony stimulating factor (M-CSF), suggesting that 
this differentiation plays an important role in bone biology. In the 
bone microenvironment, RANKL is produced by bone marrow 
stromal cells and osteoblasts, while in a bone tumor environ-
ment, it can be produced by other cell types, such as fibroblasts, 
epithelial cells, or T-lymphocytes, in which RANKL appears to 
be the final effector of osteoclast-mediated bone resorption (26). 
Cells from many tumor types, including multiple myeloma, 
prostate cancer, or even human neuroblastoma, can also express 
RANKL themselves (73–75). Moreover, many of the chemokines, 
cytokines, hormones, and growth factors produced by tumor cells 
are able to induce an increase in RANKL expression through 
PTH-rP, and a decrease in OPG production, thus aggravating the 
vicious cycle in bone metastases. RANK is one of the signaling 
molecules associated with worse outcomes in osteosarcoma. 
High expression of RANKL is associated with reduced survival 
in osteosarcoma, and it has been reported that osteosarcoma cell 
lines and biopsies show high expression of functional RANK, 
suggesting a potential autocrine stimulation of this pathway (76, 
77). Inhibition of RANKL using the shRNA strategy reduced 
motility and anoikis resistance in osteosarcoma cell lines, 
whereas overexpression of RANK increased OS cell motility 
without affecting cell proliferation (78). One study reported the 
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preventive effect of siRNA–RANKL on tumor progression when 
associated with the chemotherapeutic agent ifosfamide in a pre-
clinical model of osteosarcoma (79). For Ewing sarcoma, only a 
few studies are available, but it seems that these cells express only 
a low level of RANKL (3). In our case, preliminary preclinical 
studies evidenced localized but strong expression of RANKL in a 
paratibial model of Ewing sarcoma induced by an intramuscular 
injection of human A673 cells in Nude mice (80). The advantages 
of targeting RANKL have previously been reported in both bone 
metastases and primary bone tumors and might be a promis-
ing target in Ewing sarcoma (73, 74, 81, 82). Several molecules 
targeting RANKL have already proved their efficiency in other 
malignant bone pathologies, such as osteosarcoma, and might be 
a potent therapeutic agent in Ewing sarcoma.
Osteoprotegerin, a member of the TNF receptor super-family, 
is a ubiquitous secreted homodimeric cytokine able to bind 
RANKL and then inhibit the RANK/RANKL interaction, as well 
as any further osteoclast differentiation and activation (83–85). 
A disruption in the RANKL/OPG ratio in favor of RANKL has 
been shown to be responsible for severe osteolysis in a tumoral 
context (86). Accordingly, overexpressing OPG to restore this 
equilibrium between OPG and RANKL expression appears to be 
a promising approach for limiting tumor-associated bone lesions. 
For the first time, our team has shown significant therapeutic 
benefits of OPG in primary bone tumors. In a preclinical model 
of osteosarcoma, OPG delivered by non-viral gene transfer effec-
tively inhibited tumor growth and tumor-associated osteolysis, 
significantly increasing animal survival (81). Several studies have 
tested OPG overexpression in OS and Ewing sarcoma preclinical 
models with promising results, especially in osteosarcoma (81). 
Moreover, despite its clinical efficiency in preventing osteolytic 
lesions, a major issue for OPG-Fc administration as an adjuvant 
therapeutic agent in a tumor context is its ability to inhibit the 
apoptosis induced by TNF-related apoptosis inducing ligand 
(TRAIL) (87). The dual effect of OPG may inhibit TRAIL-
induced apoptosis of tumor cells, a natural mechanism for 
preventing tumor development (88). In addition, TRAIL’s ability 
to both induce apoptosis in sensitive Ewing Sarcoma cell lines 
and prevent tumor development has already been demonstrated 
in vitro by Wietzerbin’s team and in vivo by our team in a preclini-
cal model induced by intratibial injection of Ewing sarcoma cells 
in nude mice (89, 90). To avoid the potential protumoral effect 
of OPG, the recombinant protein RANK-Fc, the soluble form 
of RANK, could be used in Ewing sarcoma to block RANKL 
activity. RANK-Fc is unable to bind TRAIL, and its efficacy 
has already been demonstrated in preventing tumor-associated 
osteolysis and, indirectly, tumor growth in preclinical models 
of bone metastases, such as prostate, lung, and breast cancer 
(91–93). Our team also showed how RANK-Fc, when delivered 
by non-viral gene transfer, is able to prevent osteolytic lesions 
and tumor development, thus inducing an increase in animal 
survival in a preclinical rodent model of osteosarcoma (82). The 
same efficacy can be expected in Ewing sarcoma but remains 
to be tested. For clinical transfer, denosumab is a monoclonal 
antibody specific for human RANKL, which was initially devel-
oped to treat osteoporosis (94). It was then used for painful bone 
metastases with effective results (95–98). It was subsequently 
found to also be effective for giant cell tumor of bone, a benign 
but destructive neoplasm with severe osteolytic lesions, in which 
transformed mononuclear cells secrete high levels of RANKL, 
causing osteoclast hyperactivity (99).
TARGeTiNG OTHeR ASPeCTS OF THe 
BONe MiCROeNviRONMeNT iN ewiNG 
SARCOMA
Besides bone cells themselves, the tumor microenvironment 
of primary bone tumors provides factors that are favorable for 
tumor initiation, progression, therapy resistance, or metastatic 
dissemination. Of the different constituents or aspects of this 
peculiar microenvironment, special attention has been paid to 
hypoxia, escape from the immune system, angiogenesis, growth 
factors from the microenvironment, and modification of the 
microenvironment itself by therapeutic agents that may interfere 
with tumor progression (Figure 4).
Hypoxia is an important condition in the tumor cell microen-
vironment associated with a more aggressive phenotype and poor 
prognosis of many cancers in adults. For example, intratumoral 
hypoxia is a common finding in breast cancer associated with 
a significantly increased risk of metastasis and patient mortality 
(100). Hypoxia-inducible factors activate the transcription of a 
large battery of genes encoding proteins that promote primary 
tumor vascularization and growth, stromal cell recruitment, 
extracellular matrix remodeling, pre-metastatic niche forma-
tion, cell motility, local tissue invasion, extravasation at sites of 
metastasis, and maintenance of the cancer stem cell phenotype 
that is required to generate secondary tumors. It is also known 
that severe and long-lasting hypoxia results in necrosis, thus 
being correlated with unfavorable outcome. Concerning Ewing 
sarcoma, a clinical study previously reported a strong correlation 
between the presence and the amount of necrotic areas in the 
tumor with the risk of metastases (101). In addition, Aryee et al. 
reported that HIF-1α expression was detectable in 18/28 primary 
tumors from the Ewing sarcoma family and that EWS-FLI1 was 
up-regulated in a HIF-1α-dependent manner (102). In addition, 
this study revealed that hypoxia stimulated the invasiveness 
and soft agar colony formation of Ewing sarcoma cells in vitro. 
Further studies suggest that EWS-FLI1 regulation in an hypoxic 
environment may occur at the posttranscriptional level, which is 
supported by the observation that HIF-1α-activated genes, such 
as VEGF, Aldolase-C, GLUT-1, CA9, and IGFBP3, were increased 
under hypoxia, whereas EWS-FLI1 RNA expression remained 
unchanged (103). It is also suggested that hypoxia increases 
Ewing sarcoma malignancy through enhancing invasive and 
colony-formation capacities. Furthermore, it could be proposed 
that hypoxia may contribute to the aggressive metastatic behav-
ior of Ewing sarcoma, as HIF-1α and EWS-FLI1 may function 
together in both synergistic and antagonistic cross-talk under 
hypoxia conditions. Therefore, drugs that target hypoxia need to 
be tested in Ewing sarcoma models.
Crosstalk between the bone niche and the immune system, known 
as “osteoimmunology,” has been suggested as being a potential 
target for bone tumor treatment. There is a well-recognized link 
FiGURe 4 | Particular bone microenvironment that may affect tumor initiation, progression, or dissemination. Bone microenvironment is characterized by 
high hypoxia, high acidity, OPG release, and the influence of the cytokines (IL-6, IL-8, IL-11, and TNF-α) produced by cells from the immune system. IL, interleukin; 
TNF, tumor necrosis factor; OPG, osteoprotegerin.
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between bone constituents and the immune system, leading to 
recent efforts to elucidate the functions of molecules expressed in 
both bone and immune cells. A recent review nicely describes the 
complexity of the interaction between the skeletal and immune 
systems, suggesting that their interdependency needs to be taken 
into consideration when designing therapeutic approaches for 
either of the two systems (31). For example, denosumab, which 
was originally used to specifically target bone resorption, is now 
under evaluation for its effect on the long-term immune response. 
As both the bone and immune systems are often disrupted in can-
cer, they may be crucial in regulating tumor growth and progres-
sion. Certain therapies, such as BPs and RANKL-targeted drugs 
that aim to reduce pathological osteolysis in cancer, may interact 
with the immune system, thus providing favorable effects on 
survival. Another interesting publication reported that dynamic 
tumor–host immune interactions within the tumor microenvi-
ronment may polarize immune responses in  situ, influencing 
tumor development and/or progression (104). They studied the 
nature of tumor–host immune interactions within the Ewing 
sarcoma microenvironment, analyzing the presence and spatial 
distribution of infiltrating CD8(+)(/)CD4+ T-lymphocytes 
in therapy-naive Ewing sarcoma. They observed that tumor-
infiltrating T-cells contained significantly higher percentages of 
CD8(+) T-lymphocytes than stroma-infiltrating cells, suggesting 
preferential migration of this type of T-cell into tumor areas. Their 
results indicated that an inflammatory immune microenviron-
ment with high expression of type 1-associated chemokines may 
be critical for the recruitment of CD8(+) T-lymphocytes express-
ing the corresponding chemokine receptors. The observed impact 
of tumor-infiltrating CD8(+) T-lymphocytes is consistent with 
there being a role for adaptive anti-tumor immunity in prevent-
ing Ewing sarcoma from progressing. Recognizing the merits and 
exploitation/induction of an inflammatory microenvironment 
may thus improve the efficacy of natural responses against, and 
(adoptive) immunotherapeutic approaches for, Ewing sarcoma.
With regard to angiogenesis, VEGF-165 expression in the 
tumor microenvironment has been shown to influence the differ-
entiation of bone marrow-derived pericytes, which play a part in 
the vasculature of Ewing sarcoma (105). One year later, the same 
team demonstrated that VEGF-165 contributed to the osteolytic 
process in Ewing sarcoma by upregulating RANKL (106). They 
showed that VEGF-165, together with EWS-FLI1, increased 
RANKL promoter activity. This increase in RANKL gene expres-
sion in the bone marrow microenvironment during the metastatic 
process may be involved in tumor-induced bone osteolysis.
Other growth factors present in the bone microenvironment, 
such as basic FGF, may play a part in tumor progression as they 
enhance cell motility and invasion of the Ewing sarcoma family of 
tumors by activating the FGFR1–PI3K–Rac1 pathway (107). The 
authors therefore conclude that the bFGF–FGFR1–PI3K–Rac1 
pathway in the bone microenvironment may have a significant 
role in the invasion and metastasis of the Ewing sarcoma family 
of tumors.
Conversely, therapeutic agents, such as ZOL, are able to modify 
the bone microenvironment surrounding primary or disseminated 
tumor cells, as has been reported in breast cancer recurrence in 
bone (108). Treatment of mice with ZOL induced a rapid increase 
in trabecular bone volume versus controls, which was reflected by 
a significant reduction in osteoclast and osteoblast numbers per 
millimeter in trabecular bone, and reduced bone marker levels 
in serum. Pre-treatment with ZOL caused an accumulation of 
extracellular matrix in the growth plate associated with a trend 
for preferential homing of tumor cells to osteoblast-rich areas of 
bone, but without affecting the total number of tumor cells. The 
number of circulating tumor cells was reduced in ZOL-treated 
animals. Although this study concerns breast cancer, osteoblasts 
may be key components in the bone metastasis/tumor niche, and 
therefore a potential therapeutic target, at least in breast cancer. 
This hypothesis therefore needs to be studied extensively in 
primary bone tumors, including Ewing sarcoma.
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BONe MiCROeNviRONMeNT MODeLiNG 
iN ewiNG SARCOMA
As the microenvironment, and especially the bone tumor micro-
environment, can both inhibit and facilitate tumor growth and 
metastatic dissemination, better modelization of the tumor bone 
niche is needed to characterize tumor cell–stroma interaction in 
depth. It has been shown that osteoblasts, osteoclasts, fibroblasts, 
myeloid cells, and mesenchymal stem cells (MSCs) play essen-
tial roles in primary tumor growth and metastasis (109, 110). 
However, current in  vitro approaches are far from replicating 
the native in vivo milieu in which tumors develop, a necessary 
condition for advancing cancer research and translating new 
therapies into clinical practice. Most preclinical anti-neoplastic 
drug testing is still carried out on conventional 2D cell culture 
systems. Although these systems mimic some of the phenotypic 
traits observed clinically, they are limited in their ability to 
model the full range of microenvironmental interactions, such 
as 3D cell–cell and cell–extracellular matrix interactions. Several 
teams have thus established ex vivo 3D bone tumor models that 
closely mimic the morphology, growth kinetics, and protein 
expression profile of human tumors, including Ewing sarcoma 
(111–113). For example, Ewing sarcoma cells cultured in porous 
3D electrospun poly(ϵ-caprolactone) scaffolds were not only 
more resistant to traditional cytotoxic drugs than cells in 2D 
monolayer cultures but also exhibited remarkable differences 
in the expression pattern of the IGF-1R/mTOR pathway (111). 
This 3D model of the bone microenvironment may therefore 
have broad applicability for mechanical studies of bone sarcomas 
and shows the potential for increasing preclinical evaluation of 
anti-neoplastic drug candidates for these malignancies. In the 
same way, Villasante et al. described a bioengineered model of 
human Ewing sarcoma that mimics the native bone tumor niche 
with high biological fidelity (113). In this model, cancer cells that 
have lost their transcriptional profiles after monolayer culture re-
express genes related to focal adhesion and cancer pathways. The 
bioengineered model recovers the original hypoxic and glycolytic 
tumor phenotype and makes possible re-expression of angiogenic 
and vasculogenic mimicry features that favor tumor adaptation. 
Differentially expressed genes between the monolayer cell culture 
and native tumor environment may thus be potential therapeutic 
targets that could be explored using the bioengineered tumor 
model.
In addition, Ludwig’s team has highlighted a number of 
innovative methods used to fabricate biomimetic Ewing sarcoma, 
including both the surrounding cellular milieu and the extracel-
lular matrix. These methods suggest potential applications for 
advancing our understanding of the biology of Ewing sarcoma, 
preclinical drug testing, and personalized medicine (112).
Finally, it appears that the bone microenvironment should 
be modelized in order to analyze the response of bone tumor 
cells to drug screening under optimal conditions. Currently, few 
preclinical models of bone cancer, and particularly Ewing sar-
coma, mirror the site of the disease in patients, as they are mostly 
subcutaneous or intramuscular xenografts (114).
For metastasis in Ewing sarcoma, intravenous models induced 
in non-obese diabetic/severe combined immunodeficient (NSG) 
mice showed a pattern of disease spread similar to that found in 
patients, but only 23% of the experimental mice developed assess-
able bone metastases (115). It is therefore preferable to develop 
orthotopic models that involve direct injection of Ewing sarcoma 
cells at the clinically relevant site, i.e., intrafemoral. This type of 
injection in immunocompromized mice provides a technically 
feasible and reproducible approach, resulting in tumors that 
are detectable by palpation or in vivo imaging, and that closely 
resemble those observed in patients (116). The importance of 
such orthotopic models for testing potential new drugs at the 
preclinical level was emphasized in the study by Odri et al. (65), 
comparing how tumor progression responds to ZOL in two 
models of Ewing sarcoma: one induced by tumor cell injection in 
the medullar cavity of tibia and the other with initial progression 
in soft tissue (65). ZOL significantly inhibited Ewing sarcoma cell 
progression only in the intratibial model and showed no effect in 
the soft tissue. These results strongly suggest the importance of 
considering the complete bone microenvironment when testing 
new drugs, especially in the case of bone tumors, such as Ewing 
sarcoma. Recently, Vormoor et al. also developed an interesting 
preclinical orthotopic model of Ewing sarcoma in NSG mice, 
reproducing the biology of the tumor–bone interactions observed 
in human disease (117). In this model, the Ewing sarcoma cells 
have been modified allowing in vivo monitoring of disease pro-
gression (115). The authors therefore demonstrated the utility of 
small animal bioimaging for tracking disease progression, mak-
ing this model a useful assay for preclinical drug testing.
CONCLUSiON – PeRSPeCTiveS
Despite improvements in poly-chemotherapy combinations 
and surgical approaches preserving limbs from amputation, one 
group of Ewing sarcoma patients still remains at high risk, with 
poor survival rates. These patients present with metastatic disease 
at diagnosis or respond poorly to chemotherapy due to acquired 
resistance. New therapeutic options are thus needed. Given the 
growing interest in the microenvironment and its recognized 
involvement in cancer initiation and progression, it is relevant 
to propose therapeutic strategies that target molecular and/or 
cellular protagonists of the bone tumor microenvironment in the 
case of Ewing sarcoma.
Most on-going studies focus on bone cells, especially osteo-
clasts, either by directly targeting them or inhibiting RANKL, the 
main cytokine involved in osteoclast activation. These strategies 
(BPs, anti-RANKL: denosumab) could be proposed not only to 
target the bone component of the primary tumor but also to tar-
get bone/bone marrow metastases, the worst prognosis factor for 
Ewing sarcoma patients, as confirmed in the R3 arm of the latest 
EuroEWING99 trial (survival rate of <20% at 5 years). However, 
as expected, these strategies have no effect in preclinical models of 
pulmonary metastases, which remains the main cause of mortal-
ity in Ewing sarcoma patients (the prognosis for patients with 
lung-only metastases is 30% survival at 5  years). However, the 
strategies could be proposed for pulmonary metastatic patients 
or patients with soft tissue Ewing sarcoma if they are in synergy 
with current or targeted therapies, as suggested by our preclini-
cal studies combining ZOL with ifosfamide (65).
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